Browse
Submit Data
Databases
API
Help

Dataset Information

59 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

ABSTRACT: The efficacy of the epidermal growth factor receptor (EGFR) inhibitors have been demonstrated in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC). Dermatological reactions can cause significant physical and psycho-social discomfort to patients. In the present study, the investigators evaluated the effect of epidermal growth factor (EGF) ointment on EGFR inhibitor-related skin side effects (ERSEs).

DISEASE(S): Non-small Cell Lung Cancer,Colorectal Cancer,Pancreatic Cancer

PROVIDER: 2177761 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

The network response to Egf is tissue-specific

Project description:Epidermal growth factor receptor (EGFR)-driven signaling regulates fundamental cellular processes. Dysregulated signaling via EGFR is implicated in numerous disease pathologies, and distinct EGFR-associated disease etiologies are known to be tissue-specific. The molecular basis of this tissue specificity remains poorly understood. Most studies of EGFR signaling to date have been performed in vitro or in tissue-specific mouse models of disease, which has limited insight into EGFR signaling patterns in healthy tissues. Here, we carried out integrated phosphoproteomic, proteomic, and transcriptomic analyses of signaling changes across various mouse tissues in response to short-term stimulation with the Egfr ligand Egf. We show how both baseline and Egf-stimulated signaling behaviors differ between tissues. Moreover, we propose how baseline phosphorylation and total protein levels may be associated with clinically relevant tissue-specific Egfr-associated phenotypes. Altogether, our analyses illustrate tissue-specific effects of Egf stimulation and highlight potential links between underlying tissue biology and Egfr signaling output.

2025-03-06 | GSE262676 | GEO

The network response to Egf is tissue-specific

Project description:Epidermal growth factor receptor (Egfr)-driven signaling regulates fundamental homeostatic processes. Dysregulated signaling via Egfr is implicated in numerous disease pathologies and distinct Egfr-associated disease etiologies are known to be tissue-specific. The molecular basis of this tissue specificity remains poorly understood. Most studies of Egfr signaling to date have been performed in vitro or in tissue-specific mouse models of disease, which has limited insight into Egfr signaling patterns in healthy tissues. Here, we carried out integrated phosphoproteomic, proteomic, and transcriptomic analyses of signaling changes across various mouse tissues in response to short-term stimulation with the Egfr ligand Egf. We show how both baseline and Egf-stimulated signaling behaviors differ between tissues. Moreover, we propose how baseline phosphorylation and total protein levels may be associated with clinically relevant tissue-specific Egfr-associated phenotypes. Altogether, our analyses illustrate tissue-specific effects of Egf stimulation and highlight potential links between underlying tissue biology and Egfr signaling output.

2025-03-08 | PXD050402 | Pride

EGF decreases the abundance of microRNAs that restrain oncogenic transription factors

Project description:Epidermal growth factor (EGF) stimulates cells by launching gene expression programs that are frequently deregulated in cancer. MicroRNAs, which attenuate gene expression by binding complementary regions in messenger RNAs, are broadly implicated in cancer. Using genome-wide approaches, we showed that EGF stimulation initiates a coordinated transcriptional program of microRNAs and transcription factors. The earliest event involved a decrease in the abundance of a subset of 23 microRNAs. This step permitted rapid induction of oncogenic transcription factors, such as c-FOS, encoded by immediate early genes. In line with roles as suppressors of EGF receptor (EGFR) signaling, we report that the abundance of this early subset of microRNAs is decreased in breast and in brain tumors driven by the EGFR or the closely related HER2. These findings identify specific microRNAs as attenuators of growth factor signaling and oncogenesis 24 conditions: time course of 8 hours of HeLa and MCF10A cells after EGF or SERUM stimulation

2012-09-06 | E-GEOD-40626 | biostudies-arrayexpress

EGF decreases the abundance of microRNAs that restrain oncogenic transription factors

2012-09-06 | GSE40626 | GEO

Egf

Project description:Rattus norvegicus Egf, epidermal growth factor [Source:RGD Symbol;Acc:2542], is expressed in 5 baseline experiment(s);

| ENSRNOG00000053979 | ExpressionAtlas

EGF

Project description:Monodelphis domestica EGF, epidermal growth factor [Source:NCBI gene;Acc:100619143], is expressed in 2 baseline experiment(s);

| ENSMODG00000005870 | ExpressionAtlas

IL-13 and EGF receptor signaling in normal human bronchial epithelial cells

Project description:To investigate the role of interleukin-13 (IL-13) and the epidermal growth factor (EGF) receptor pathway in controlling mucus metaplasia, normal human bronchial epithelial (NHBE) cells were cultured on air-liquid interface for 14 days and were treated with IL-13, anti-EGFR antibody or both during the final 48 h of culture. Keywords: Stimulus response

2006-11-01 | GSE4804 | GEO

EGF

Project description:Sus scrofa EGF, epidermal growth factor [Source:VGNC Symbol;Acc:VGNC:98921], is expressed in 1 baseline experiment(s);

| ENSSSCG00000009134 | ExpressionAtlas

egf

Project description:Xenopus tropicalis egf, epidermal growth factor [Source:Xenbase;Acc:XB-GENE-951823], is expressed in 1 baseline experiment(s);

| ENSXETG00000013368 | ExpressionAtlas

EGF

Project description:Macaca mulatta EGF, epidermal growth factor [Source:VGNC Symbol;Acc:VGNC:72171], is expressed in 1 baseline experiment(s);

| ENSMMUG00000010043 | ExpressionAtlas